Recombinant human endostatin (rh‐endostatin) inhibits the proliferation of vascular endothelial cells through multiple targets, thereby suppressing angiogenesis and tumor growth.4 It has been reported that the combination of rh‐endostatin with cisplatin/vinorelbine significantly increased time to progression and overall response rate (ORR) in NSCLC patients.5 On the basis of this study, the China Food and Drug Administration (CFDA) approved rh‐endostatin as the first‐line treatment for advanced NSCLC patients in 2005. Here, COL18A1 is linked to non-small cell lung carcinoma.